Together, HemCon and ProMetic will develop and validate a sterile, single-use antibody capture device for the removal of isoagglutinin antibodies.
The exclusive agreement covers the development of a new capture device, based on ProMetic’s affinity adsorbent technology, for both single source and pooled plasma in combination with the HemCon lyophilized plasma (LyP) system currently under development.
Under the terms of the agreement, the development program will be funded by HemCon and both companies will jointly own all collaboration technology for the new device that is intended for the LyP system. In addition, HemCon will have exclusive purchasing rights for the device and ProMetic will be its sole supplier for the LyP system.
John Morgan, CEO of HemCon, said: “HemCon is pleased to collaborate with ProMetic to develop this innovative capture device. ProMetic has worked with many influential companies and organizations, including the American Red Cross, to ensure the purification of blood, plasma and plasma-derived products. As we continue to develop our new LyP system, ProMetic’s technology will help us broaden our donor supply pool and increase the resuscitation fluid options for our military and civilian customers.”